NCT04701307: An ongoing trial by M.D. Anderson Cancer Center
This trial is ongoing. It must report results 11 months, 2 weeks from now.
Full data
| Full entry on ClinicalTrials.gov | NCT04701307 |
|---|---|
| Title | Niraparib (PARP Inhibitor) Plus Dostarlimab (Anti-PD1) for Small Cell Lung Cancer (SCLC) and Other High-Grade Neuroendocrine Carcinomas (NEC) |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Feb. 1, 2021 |
| Completion date | Nov. 30, 2025 |
| Required reporting date | Nov. 30, 2026, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | None |